Please login to the form below
PD-1
This page shows the latest PD-1 news and features for those working in and with pharma, biotech and healthcare.
Pivotal data sets up Tecentriq filing in small cell lung cancer
Roche’s PD-L1 inhibitor Tecentriq has become the first cancer immunotherapy to improve survival in extensive-stage small cell lung cancer (ES-SCLC), putting it on course to end a ... The company is currently running a phase III trial ( KeyNote-604) of
Latest news
-
BMS presses go on Nektar combo pivotal trials, despite data debate
The phase I/II PIVOT trial met the criteria needed to advance PD-1 inhibitor Opdivo (nivolumab) and CD122-biased agonist NKTR0214 into pivotal trials in melanoma, renal cell carcinoma and ... For BMS, the partnership with Nektar is part of an attempt to
-
Daily Brief: Immunotherapy firm Advaxis cuts back, Pfizer wins price gouging appeal
goals. Once such company is Advaxis, which is struggling after a trial of its lead drug axalimogene filolisbac and AstraZeneca’s PD-L1 checkpoint inhibitor Imfinzi was put on clinical hold ... However if it can’t secure a partner, it will wind down
-
Daily Brief: Keytruda and microbiome synergy, Pfizer's files PARP contender and more
The phase I study will evaluate the benefits in patients who progressed on prior PD-1 inhibitor therapy with renal, bladder, melanoma and non-small cell lung cancer.
-
ASCO data back up Merck’s dominance in lung cancer
Crucially, the trial enrolled patients with PD-L1 expression levels of 1% or more, a much broader patient population than was tested in the earlier KEYNOTE-024 trial of Keytruda monotherapy ... That includes Roche, which reported updated data from the
-
J&J moves quickly ahead with trials of myeloma CAR-T
as well as some in-house projects such as PD-1 checkpoint inhibitor JNJ-63723283, but it is still a minnow among the big fish in immuno-oncology.
More from news
Approximately 21 fully matching, plus 233 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2018
Option, collaboration. 1, 063. Syros Pharmaceuticals/ Incyte. Gene control platform to identify up to seven therapeutic targets with a focus in myeloproliferative neoplasms. ... used to progress the clinical development of the company's immuno-oncology
-
The good, the bad and the ugly
But that doesn’t tell the whole story. Pfizer comfortably remains the world’s largest pharma company (by global Rx sales), with an estimated 12.1% growth in 2017, lifting its ... Companies are looking to pair their PD-1/PD-L1 checkpoint inhibitors
-
European venture funding for the life science sector
is likely to accelerate interest - the sheer number of combination therapies and PD-1/PD-L1 inhibitors could result in a commoditisation of this area that could threaten returns for venture
-
Pharma deals continue to slide
1, 410 (upfront 80). WuXi Biologics and Gloria Pharma (CN). Arcus Biosciences (US). ... Licence to develop and commercialise. GLS-010, anti-PD-1 antibody in phase I for treatment of cancer.
-
Deal Watch January 2017
3, 050. Pieris Pharmaceuti-cals. Servier. Exclusive licence outside USA. PRS 332 PD-1-targeting bispecific checkpoint inhibitor and 4 other candidates. ... 775. BMS | Ono. Merck. Patent settlement. PD-1 antibody Keytruda - (pembrolizumab).
More from intelligence
Approximately 0 fully matching, plus 24 partially matching documents found.
Latest appointments
-
Crescendo Biologics appoints Dr Kevin Johnson as chairman
Crescendo's discovery programmes are focused on the development of innovative medicines for the treatment of cancer, including its proprietary Humabody Drug Conjugates (HDCs) and checkpoint modulators such as ... 1 Humabodies.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
A stumble, but not a fall – what’s next for Opdivo?
Opdivo works via PD-1 immune checkpoint inhibition, which involves reactivating T-cells (a subtype of white blood cell) and decreasing tumor growth.
-
Immuno-oncology: The market opportunity for PD-1/PD-L1s
Immuno-oncology: The market opportunity for PD-1/PD-L1s. Immuno-oncology is the new frontier in cancer treatment. ... Of these therapies, immune checkpoint inhibitors are showing particular promise.Our latest infographic is a snapshot of the PD-1/PD-L1
-
Immuno-oncology: The market opportunity for PD-1/PD-L1s
Immuno-oncology: The market opportunity for PD-1/PD-L1s. Immuno-oncology is the new frontier in cancer treatment. ... Of these therapies, immune checkpoint inhibitors are showing particular promise.Our latest infographic is a snapshot of the PD-1/PD-L1
-
Research Partnership
Published in PBIRG Perspective, May 2016, vol. 18 No.1, By Julie Denny, Marketing Director. ... Published in PBIRG Perspective, May 2016, vol. 18 No.1, By Julie Denny, Marketing Director.
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Featured jobs
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Senior Project Manager - Medical Writing
-
Great salary and bebefits
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Business Unit Head, Medical Communications, London
-
Excellent package
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- NHS England says yes to Roche's Hemlibra
- Moving annual total (MAT)
- Roche keeps Venclexta train rolling with new leukaemia filing
- Communiqué Awards 2018: Winners in pictures - Communiqué Awards 2016
- Pfizer enters late-stage haemophilia B gene therapy trial
- Porterhouse Medical strengthens the team with three new members.
- Developing advocacy in the pharmaceutical industry.
- Roche’s Tamiflu successor hits the mark in complicated flu
- Novartis launch NET cancer community app
- J&J’s Invokana aces diabetic kidney disease trial, setting up filings
PMHub
Genetic Digital
We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
